Epigenetic reprogramming synergizes with PD-1/PD-L1 inhibition for cell-targeted therapy in hepatocellular carcinoma

被引：0
|
作者：
Sukowati, Caecilia [1 ,2 ,3 ]
Cabral, Loraine Kay [3 ,4 ]
Anfuso, Beatrice [5 ]
Tiribelli, Claudio [3 ]
机构：
[1] Natl Res & Innovat Agcy Indonesia, Jakarta, Indonesia
[2] Eijkman Res Ctr Mol Biol, Jakarta, Indonesia
[3] Fdn Italiana Fegato ONLUS, Basovizza, Italy
[4] Univ Trieste, Doctoral Sch Mol Biomed, Trieste, Italy
[5] Univ Trieste, Dept Life Sci, Trieste, Italy
来源：
JOURNAL OF HEPATOLOGY | 2023年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
SAT-273
引用
收藏
页码：S559 / S559
页数：1
相关论文
共 50 条
  • [1] Cell-targeted PD-1 agonists that mimic PD-L1 are potent T cell inhibitors
    Curnock, Adam P.
    Bossi, Giovanna
    Kumaran, Jyothi
    Bawden, Lindsay J.
    Figueiredo, Rita
    Tawar, Rajeevkumar
    Wiseman, Katherine
    Henderson, Emma
    Hoong, Sec Julie
    Gonzalez, Veronica
    Ghadbane, Hemza
    Knight, David Eo
    O'Dwyer, Ronan
    Overton, David X.
    Lucato, Christina M.
    Smith, Nicola Mg
    Reis, Carlos R.
    Page, Keith
    Whaley, Lorraine M.
    McCully, Michelle L.
    Hearty, Stephen
    Mahon, Tara M.
    Weber, Peter
    JCI INSIGHT, 2021, 6 (20)
  • [2] PD-L1/PD-1 In Hepatocellular Carcinoma: An Institutional Review
    Poveda, Julio
    Duarte, Melissa
    Jones, Patricia Denise
    Chowdhury, Aneesa
    Brown, Kevin
    Garcia-Buitrago, Monica
    LABORATORY INVESTIGATION, 2019, 99
  • [3] PD-L1/PD-1 In Hepatocellular Carcinoma: An Institutional Review
    Poveda, Julio
    Duarte, Melissa
    Jones, Patricia Denise
    Chowdhury, Aneesa
    Brown, Kevin
    Garcia-Buitrago, Monica
    MODERN PATHOLOGY, 2019, 32
  • [4] Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma
    Tran, Linda
    Allen, Clint T.
    Xiao, Roy
    Moore, Ellen
    Davis, Ruth
    Park, So-Jin
    Spielbauer, Katie
    Van Waes, Carter
    Schmitt, Nicole C.
    CANCER IMMUNOLOGY RESEARCH, 2017, 5 (12) : 1141 - 1151
  • [5] POTENTIAL AS BIOMARKERS OF SOLUBLE PD-1 AND PD-L1 IN HEPATOCELLULAR CARCINOMA
    Kanzaki, Hiroaki
    Chiba, Tetsuhiro
    Kato, Naoya
    HEPATOLOGY, 2019, 70 : 1218A - 1218A
  • [6] Clinical outcomes and influencing factors of PD-1/PD-L1 in hepatocellular carcinoma
    Wang, Jiting
    Li, Jun
    Tang, Guiju
    Tian, Yuan
    Su, Song
    Li, Yaling
    ONCOLOGY LETTERS, 2021, 21 (04) : 1 - 8
  • [7] PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
    Li, Qian
    Han, Jingjing
    Yang, Yonglin
    Chen, Yu
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [8] Progression patterns in patients with advanced hepatocellular carcinoma treated with local therapy, targeted drugs, and PD-1/PD-L1 inhibitors
    Zhao, Yanan
    Wu, Di
    Yao, Quanjun
    Yuan, Hang
    Hu, Hongtao
    Li, Hailiang
    CENTRAL EUROPEAN JOURNAL OF IMMUNOLOGY, 2024, 49 (02) : 147 - 154
  • [9] PD-1 and PD-L1 Inhibitors as Salvage Therapy for Urothelial Carcinoma
    Sonpavde, Guru
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (11): : 1073 - 1074
  • [10] Defects in Macrophage Reprogramming in Cancer Therapy: The Negative Impact of PD-L1/PD-1
    Cai, Hao
    Zhang, Yichi
    Wang, Jian
    Gu, Jinyang
    FRONTIERS IN IMMUNOLOGY, 2021, 12
12345